SCHEMBL10944142

SCHEMBL10944142

COc1c(N)ccc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42
TUBB2B Q9BVA1 1/20 0.42
TUBB1 Q9H4B7 1/20 0.42
HTR2C P28335 3/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR7 P34969 1/20 0.40
HTR5A P47898 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30126262 1.00 TUBB4A (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10992767 0.82 ALDH1A1 (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2426464 0.82 ALDH1A1 (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2355429 0.80 ALDH1A1 (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29536407 0.80 ALDH1A1 (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24824751 0.80 CYP3A4 (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5238486 0.80 IDO1 (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL8304430 0.80 ALDH1A1 (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Hydrochloric Acid SCHEMBL8173396 0.78 ALDH1A1 (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22366678 0.78 HTR2C (0.37) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4085141-A Process for the preparation of anilines meta-substituted by chlorine BAYER AKTIENGESELLSCHAFT (DT) 1978-04-18 US claimed
EP-3507275-B1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC (US) 2023-04-26 EP disclosed
EP-3507275-B1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC (US) 2023-04-26 EP disclosed
WO-2022266458-A1 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
US-11040954-B1 CXCR3 receptor agonists RECEPTOS LLC (US) 2021-06-22 US disclosed
US-11040954-B1 CXCR3 receptor agonists RECEPTOS LLC (US) 2021-06-22 US disclosed
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC 2019-11-14 US disclosed
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC 2019-11-14 US disclosed
EP-3507275-A1 CXCR3 RECEPTOR AGONISTS Celgene International II Sarl (CH) 2019-07-10 EP disclosed
WO-2018045246-A1 CXCR3 RECEPTOR AGONISTS CELGENE INTERNATIONAL II SARL (CH) 2018-03-08 WO disclosed
EP-0051782-B1 PROCESS FOR THE MANUFACTURE OF M-HALOGENATED ANILINES BAYER AG (DE) 1984-05-23 EP disclosed
US-4429156-A Process for the preparation of m-halogen-substituted anilines BAYER AKTIENGESELLSCHAFT (DE) 1984-01-31 US disclosed
US-4418213-A HYDRODEHALOGENATION LEWIS ACID AND NOBLE METAL CATALYSTS RHONE-POULENC AGROCHIMIE (FR) 1983-11-29 US disclosed
EP-0069907-A2 Process for preparing m-chloro-substituted anilines BAYER AG (DE) 1983-01-19 EP disclosed
US-4351959-A Process for preparation of anilines substituted by chlorine in the meta-position RHONE-POULENC AGROCHIMIE (FR) 1982-09-28 US disclosed
US-4340759-A Process for the preparation of anilines substituted by chlorine in the meta-position RHONE-POULENC AGROCHIMIE (FR) 1982-07-20 US disclosed
EP-0051782-A1 Process for the manufacture of m-halogenated anilines BAYER AG (DE) 1982-05-19 EP disclosed
US-4324914-A Process for preparation of anilines substituted by chlorine in the meta-position RHONE-POULENC AGROCHIMIE (FR) 1982-04-13 US disclosed
US-4193937-A DECHLORINATION OF CHLOROANILINES, SELECTIVE HYDROGENATION CATALYSTS OF NOBLE METAL AND SULFUR BAYER AKTIENGESELLSCHAFT (DE) 1980-03-18 US disclosed
US-4085141-A Process for the preparation of anilines meta-substituted by chlorine BAYER AKTIENGESELLSCHAFT (DT) 1978-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040954-B1 CXCR3 receptor agonists CXCR3, CXCR1, CCR7 TUBB4A 2165/4885TUBB 2386/4885TUBA3C 2372/4885
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS CXCR3, CXCR1, CCR7 TUBB4A 2165/4885TUBB 2386/4885TUBA3C 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.